Presentation is loading. Please wait.

Presentation is loading. Please wait.

Short and Long term function and survival of other graft harvested as part of a multiorgan procurement including the intestine Farinelli P, Troncoso J,

Published byAnnis Eileen Price Modified over 8 years ago

Similar presentations

Presentation on theme: "Short and Long term function and survival of other graft harvested as part of a multiorgan procurement including the intestine Farinelli P, Troncoso J,"— Presentation transcript:

1 Short and Long term function and survival of other graft harvested as part of a multiorgan procurement including the intestine Farinelli P, Troncoso J, Bertolotti A, Lenz M, Sanchez N, Fortunato R, Caravello E, Imperiali N, Dip M, Sanchez Claria R, Arriola M, De Arteaga J, Pujol Soler G, Gil O, Mc Cormack L, Bota E, Inventarza O, Gaite L, Hyon S H, Raffaele P, Illanes G, de Santibañez E, Favaloro R, Bisigniano L, Gondolesi G.

2  The use of Thymoglobulin donor pre-treatment has become standard of practice in most of the intestinal transplant programs  The reported aim has been to reduce the incidence of post-transplant GVHD  The introduction of this practice in different countries and as part of the development of new programs requires an adequate understanding and organization among all the teams involved in the procurement Introduction & Objectives AIM: Report short and long term outcomes of other graft harvested as part of the Multiorgan Procurements including the intestine in our country

3 Materials & Methods Retrospective multicentre study Multiorgan Procurements including the intestines From March 2006 to July 2011  INCUCAI web page Donors and centres data from Argentina  Data Survey sent to all programs: Graft survival Recipient survival Primary graft dysfunction (PGD) Delay Graft Function (DGF) Organ specific laboratory values: liver recipients: serum bilirubin and transaminase levels kidney-pancreas recipients: serum lipase, amylase and creatinine levels kidney recipients: creatinine levels intestine recipients: full enteric nutritional autonomy time

4 Materials & Methods  The logistics and techniques for multiple organ procurement were used according to previous publications (Starzl et al, 1984, 1987, 1991; Abu-Elmagd et al, 2000)  Donors: * Pre-treated - Metil-Prednisolone (1 gr in adults/20 mg/kg in childrens) - Thymoglobulin (1.5 mg/kg) * Selective gut decontamination was given for procurement of the intestine and the pancreas  University of Wisconsin (UW) solution was used for in situ flushing and cold storage for all organs but the kidney (HTK)  Prospective cross-match was performed for all the intestinal transplant recipients  Retrospective cross-match and Human Leukocyte Antigen matching with the recipients was used for heart, pancreas and kidney transplants.

5 Results 127/129 organs from 29 Multiorgan Procurements (19 Children and 10 Adults) were engrafted - 101 patients transplanted - 29 transplant programs at 18 hospitals nationwide (24/29 answered the survey)  5 Intra-thoracic transplantation programs 12 Hearts 2 Lungs 1 Cardio-Pulmonary Block  19 Abdominal transplantation programs 19 livers 9 kidney-pancreas 19 Kidneys 29 Intestines (22 isolated, 5 multivisceral and 2 combined)

6 OrganPatientsPGDRecoveredOrgan SurvivalPatient Survival Heart124/12 (33.3%)1/4 (25%)9/12 (75.0%) Lung20 (0%) 2/2 (100.0%) CP Block11 (100%)0 (0%)0/1 (0.0%) Results Intra-thoracic transplantation programs PGD 4/12 (33.3%) 0 (0%) 1 (100%) Recovered 1/4 (25%) 0 (0%) Organ Survival Patient Survival 9/12 (75.0%) 2/2 (100.0%) 0/1 (0.0%)

7 Results Abdominal transplantation programs OrganTxPGDDGFOrgan SurvivalPatient Survival Kidney191/19 (5.26%)4/19 (21.1%)17/19 (89.5%)18/19 (94.7%) Kidney-Pancreas9 Kydney90 (0.0%)3/9 (33.3%)*7/9 (78.0%) Pancreas93/9 (33.3%)*0 (0.0%)6/9 (66.7%)7/9 (78.0%) Liver19 Splits40 (0.0%) 4/4 (100.0%) Whole150 (0.0%) 12/15 (80.0%) Time post Tx Total Bilirubin (mg/dL) ALT (IU/L) AST (IU/L) 24 Hs 8.20±5.122378±29751250±1207 1 Week 6.54±7.1969.78±61.09150.60±263.60 1 Month 1.48±0.7030.00±13.1938.94±24.62 0 (0.0%) 4/4 (100.0%) 12/15 (80.0%)

8 Results Abdominal transplantation programs OrganTxPGDDGFOrgan SurvivalPatient Survival Kidney191/19 (5.26%)4/19 (21.1%)17/19 (89.5%)18/19 (94.7%) Kidney-Pancreas9 Kydney90 (0.0%)3/9 (33.3%)*7/9 (78.0%) Pancreas93/9 (33.3%)*0 (0.0%)6/9 (66.7%)7/9 (78.0%) Liver19 Splits40 (0.0%) 4/4 (100.0%) Whole150 (0.0%) 12/15 (80.0%) Time post Tx Amylase (IU/L) Lipase (IU/L) Creatinine (mg/dL) 48 Hs 252±134253±1995.89±3.83 1 Week 132±82304±3482.01±2.75 1 Month 100±5288±591.20±0.45 0 (0.0%)3/9 (33.3%)* 0 (0.0%) 7/9 (78.0%) 6/9 (66.7%)7/9 (78.0%)

9 Results Abdominal transplantation programs OrganTxPGDDGFOrgan SurvivalPatient Survival Kidney191/19 (5.26%)4/19 (21.1%)17/19 (89.5%)18/19 (94.7%) Kidney-Pancreas9 Kydney90 (0.0%)3/9 (33.3%)*7/9 (78.0%) Pancreas93/9 (33.3%)*0 (0.0%)6/9 (66.7%)7/9 (78.0%) Liver19 Splits40 (0.0%) 4/4 (100.0%) Whole150 (0.0%) 12/15 (80.0%) 1/19 (5.26%)4/19 (21.1%)17/19 (89.5%)18/19 (94.7%) Time post Tx Creatinine (mg/dL) 48 Hs 6.79±2.60 1 Week 4.19±2.74 1 Month 1.25±0.59 1 Year 1.04±0.30

10 Conclusions Organs harvested during MTOp including the intestine can be safely used In spite of needing longer time and team efforts, short and long term graft and patient survivals seem to be better of those obtained in regular procurements without the intestines and reported by national and international series

11 Thank you very much!

Download ppt "Short and Long term function and survival of other graft harvested as part of a multiorgan procurement including the intestine Farinelli P, Troncoso J,"

Similar presentations

Donors Per Million Population

Donors Per Million Population
Liver Transplant Outcomes in the United States : Effect of Preservation Solution DKFC Symposium July 16, 2012 John Fung, MD, PhD Cleveland Clinic Disclosure:

Liver Transplant Outcomes in the United States : Effect of Preservation Solution DKFC Symposium July 16, 2012 John Fung, MD, PhD Cleveland Clinic Disclosure:
Cells, tissues and organs All living organisms are made up of cells. Large numbers of cells group together to form tissue. Tissues can combine to form.

Cells, tissues and organs All living organisms are made up of cells. Large numbers of cells group together to form tissue. Tissues can combine to form.
Implementation of new technologies Dr Keith Cooper Southampton Health Technology Assessments Centre University of Southampton.

Implementation of new technologies Dr Keith Cooper Southampton Health Technology Assessments Centre University of Southampton.
Northwestern University Feinberg School of Medicine New Trends in organ donation and Transplantation Juan Carlos Caicedo, MD FACS Director, Hispanic Transplant.

Northwestern University Feinberg School of Medicine New Trends in organ donation and Transplantation Juan Carlos Caicedo, MD FACS Director, Hispanic Transplant.
All About Organ Transplants By: Erica Rosmus. Background: The Immune System Cells, tissues, and organs that work to keep foreign invaders away Leukocytes.

All About Organ Transplants By: Erica Rosmus. Background: The Immune System Cells, tissues, and organs that work to keep foreign invaders away Leukocytes.
What makes a pancreas allograft marginal? Peter J Friend University of Oxford.

What makes a pancreas allograft marginal? Peter J Friend University of Oxford.
Impact of expanded criteria donors on patient survival after heart, lung, liver and combined organ transplantation Quebec experience from 2003 to 2009.

Impact of expanded criteria donors on patient survival after heart, lung, liver and combined organ transplantation Quebec experience from 2003 to 2009.
Principles of Transplant Surgery Ruth Mitchell, BA, BSc, BMBS Neurosurgical Resident Royal Melbourne Hospital Thursday, 25 th March 2010.

Principles of Transplant Surgery Ruth Mitchell, BA, BSc, BMBS Neurosurgical Resident Royal Melbourne Hospital Thursday, 25 th March 2010.
ELTR 12/2008 The Present Evolution of Liver Transplantation 1. General evolution of LT in Europe 2. Donor data 3. Recipient data 4. Indications and results.

ELTR 12/2008 The Present Evolution of Liver Transplantation 1. General evolution of LT in Europe 2. Donor data 3. Recipient data 4. Indications and results.
OPTN Living Donor Committee Non Action Items Connie Davis, MD June 26, 2012.

OPTN Living Donor Committee Non Action Items Connie Davis, MD June 26, 2012.
Table SA-1: Number of Kidney Transplants by Donor Type and Re-Transplant Status Source: Canadian Organ Replacement Register, 2014, CIHI *Missing data for.

Table SA-1: Number of Kidney Transplants by Donor Type and Re-Transplant Status Source: Canadian Organ Replacement Register, 2014, CIHI *Missing data for.
© ANZOD Registry International Donor Statistics 1997 % of Multiple Organ Donors Donors PMP % Mult. Donors Eurotransplant:Germany, Austria, Belgium, Luxembourg,

© ANZOD Registry International Donor Statistics 1997 % of Multiple Organ Donors Donors PMP % Mult. Donors Eurotransplant:Germany, Austria, Belgium, Luxembourg,
Australian States 2004 - 2009 Number of Donors Per Million Population Aust 11 10 10 9 12 11 * NSW population excludes residents of the NSW Southern Area.

Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the NSW Southern Area.
© ANZOD Registry Australian States 2003 - 2008 Number of Donors Per Million Population Aust 9 11 10 10 9 12 * NSW population excludes residents of the.

© ANZOD Registry Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the.
Living Donor Kidneys in PAK 2/11 USA Primary DD Pancreas Transplants 1/1/1988 – 12/31/2010.

Living Donor Kidneys in PAK 2/11 USA Primary DD Pancreas Transplants 1/1/1988 – 12/31/2010.
Organ Donation in DCD: 10 Year Experience at the University of Michigan A Rojas-Pena, MD; L Sall, BS; K. Koch, BS; E Cooley, RN; M Gravel, RN; R Bartlett,

Organ Donation in DCD: 10 Year Experience at the University of Michigan A Rojas-Pena, MD; L Sall, BS; K. Koch, BS; E Cooley, RN; M Gravel, RN; R Bartlett,
David C. Mulligan, MD, FACS

David C. Mulligan, MD, FACS
CORR Report, 2012: CST Annual General Meeting S. Joseph Kim, MD, PhD, FRCPC Vice President, CORR Board of Directors Friday, February 24, 2012 1.

CORR Report, 2012: CST Annual General Meeting S. Joseph Kim, MD, PhD, FRCPC Vice President, CORR Board of Directors Friday, February 24,
Eurotransplant: An example of success for cross-border cooperation Bruno Meiser Eurotransplant International Foundation, Leiden, Netherlands Dept. of Cardiac.

Eurotransplant: An example of success for cross-border cooperation Bruno Meiser Eurotransplant International Foundation, Leiden, Netherlands Dept. of Cardiac.

Similar presentations

Ads by Google